A Multi-Center, Phase I, Open Label, Two Arm, Non-Randomized, Dose-Escalation, Study Of The Safety And Tolerability Of CPG 7909 In Patients Receiving Rituxan For Relapsed Or Refractory B-Cell Non-Hodgkin's Lymphoma

Trial Profile

A Multi-Center, Phase I, Open Label, Two Arm, Non-Randomized, Dose-Escalation, Study Of The Safety And Tolerability Of CPG 7909 In Patients Receiving Rituxan For Relapsed Or Refractory B-Cell Non-Hodgkin's Lymphoma

Completed
Phase of Trial: Phase I

Latest Information Update: 25 Dec 2013

At a glance

  • Drugs Agatolimod (Primary) ; Agatolimod (Primary) ; Rituximab
  • Indications Non-Hodgkin's lymphoma
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 25 Dec 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record
    • 20 Jun 2007 Pfizer has discontinued the PF-3512676 development programme because of no evidence of additional clinical efficacy compared with standard antineoplastics alone.
    • 04 Oct 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top